Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...